Zymeworks Inc.

NASDAQ:ZYME

Biotechnology

Healthcare
$26.04 -1.64%

-$0.38 today

Market cap
$1.81B
Beta
1.14
P/E (TTM)
-16.6
EPS (TTM)
-$1.37
52W Low $11.51High $29.75

Volume 1.02M

Average 0.71M

ZYME Deferred Revenue

Payments received for goods or services the company will deliver within the next year.

Zymeworks Inc.NASDAQ: ZYME

Deferred Revenue · Q3 FY2026 · quarter ended Sep 2026

Deferred revenue rises 421.1% from a year ago

Deferred revenue stood at $16.66M at the end of Q3 FY2026, up 421.1% from a year earlier and up 1.4% from the prior quarter. Over 3 fiscal years it compounded at +0.9% a year.

Context

  • Deferred revenue amounted to 1.4% of total assets at the end of Q3 FY2026, up 0.6 pp from a year earlier.
  • Deferred revenue increased in 2 of the last 3 fiscal years.

What to watch

Whether deferred revenue keeps rising in the next quarterly balance sheet after a +421.1% change from a year earlier.

Sources:Balance SheetText generated from reported figures; not investment advice.

Latest quarterSep 2026
$16.66M+1.4% QoQ
Last fiscal yearDec 2025
$2.42M-90.6% YoY
Year agoSep 2025
$3.2M+421.1% since
Deferred Revenue past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+421.1%——
1 year-90.6%——
3-year CAGR+0.9%——
5-year CAGR——
10-year CAGR——

Deferred Revenue history

USD · from the balance sheet

Latest · FY2025
2.42M USD
Year-over-year change
-90.6%

Deferred Revenue vs competitors

How ZYME compares with its peers on the latest reported figures

  • ZYME's Sep 2026 deferred revenue of $16.66M is the 3rd highest of the 11 companies compared; the peer median is $1.56M.
  • Its year-over-year change of +421.1% is the highest of 4, against a peer median of -46.2%.
  • Deferred revenue amounts to 1.4% of total assets for ZYME, versus a peer median of 0.4%.
ZYME Competitors Peer median
Deferred Revenue for ZYME and competitors
Company Period Latest balance YoY 3-year CAGR% of assets
MGNXMacroGenics, Inc.Mar 2026$67.99M +335.3%+3.0%31.2%
CTMXCytomX Therapeutics, Inc.Mar 2026$17.88M -46.2%-39.5%5.0%
ZYMEZymeworks Inc.Sep 2026$16.66M +421.1%+0.9%1.4%
CGENCompugen Ltd.Mar 2026$11.6M ——8.0%
NRIXNurix Therapeutics, Inc.Aug 2026$8.61M -66.9%-22.4%0.7%
CBIOCrescent Biopharma, Inc.Mar 2026$3.12M ——1.6%
XNCRXencor, Inc.Jun 2026$0 ——0.0%
CLDXCelldex Therapeutics, Inc.Sep 2026$0 ——0.0%
IMNMImmunome, Inc.Sep 2026$0 ——0.0%
ADCTADC Therapeutics S.A.Mar 2026$0 ——0.0%
ALXOALX Oncology Holdings Inc.Mar 2026$0 ——0.0%
Peer median (excluding ZYME) $1.56M-46.2%-22.4%0.4%

Competitors are the stored peer set for ZYME. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Balance Sheet

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Cash & Equivalents201.87M400.91M157.56M66.1M41.16M
Short-term Investments50.74M91.32M216.77M159.67M187.64M
Net Receivables15.61M33.4M19.48M55.82M4.64M
Inventory00000
Other Current Assets019.07M19.12M18.86M0
Total Current Assets288.22M544.71M412.93M300.45M233.44M
Property, Plant & Equipment (Net)49.77M47.65M37.54M34.32M0
Goodwill12.02M12.02M12.02M12.02M12.02B
Intangible Assets21.47M26.38M25.28M4.58M1.35B
Long-term Investments886K886K81.93M98.43M41.79M
Tax Assets3.07M1.35M3.62M4.39M0
Other Non-current Assets13.7M15.74M7.57M8.92M(13.29B)
Total Non-current Assets100.91M104.02M167.95M162.64M113.09M
Total Assets389.13M648.73M580.88M463.09M346.53M
Account Payables5.17M7.86M6.21M3.9M4.4M
Short-term Debt00000
Tax Payables017.08M1.81M1.38M0
Deferred Revenue02.35M3.7M25.59M2.42M
Other Current Liabilities11.1M16.01M8.68M7.49M9.67M
Total Current Liabilities71.85M95.63M55.76M88.29M42.32M
Long-term Debt00000
Deferred Tax Liabilities1.57M1.79M3.3M4.76M6.03M
Deferred Revenue (Non-current)32.94M30.59M32.94M14.61M14.61M
Other Non-current Liabilities2.65M2.98M1.61M895K278K
Total Non-current Liabilities68.19M60.14M60.31M36.03M35.71M
Total Liabilities140.04M155.77M116.07M124.32M78.03M
Common Stock741.15M906.76M1.01B1.02B1.11B
Retained Earnings(683.1M)(558.76M)(677.44M)(830.34M)(953.16M)
Accumulated OCI(6.66M)(6.66M)(6.6M)(6.95M)(6.08M)
Other Stockholders Equity00000
Minority Interest00000
Total Equity249.09M492.96M464.81M338.77M268.5M
Total Debt32.33M28.11M26.72M18.51M18.27M
Net Debt(169.53M)(372.8M)(130.84M)(47.6M)(22.89M)

Zymeworks Inc.

NASDAQ:ZYME

Intrinsic Alpha fair value

Locked

Current Price

$26.04

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.